Asthma exacerbations on benralizumab are largely non-eosinophilic

Allergy. 2021 Jan;76(1):375-379. doi: 10.1111/all.14514. Epub 2020 Aug 7.

Authors

Sophie M Poznanski¹, Manali Mukherjee², Nan Zhao², Chynna Huang², Katherine Radford², Ali A Ashkar¹, Parameswaran Nair²

Affiliations

¹ Division of Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
² Division of Respirology, Department of Medicine, McMaster University, Hamilton & Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada.

PMID: 32767484
DOI: 10.1111/all.14514

No abstract available

Keywords: airway infections; benralizumab; eosinophils; natural killer cells; severe asthma; sputum.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Asthmatic Agents* / adverse effects
Antibodies, Monoclonal, Humanized / adverse effects
Asthma* / diagnosis
Asthma* / drug therapy
Eosinophils
Humans

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
benralizumab

Grants and funding

CIHR/Canada